This retrospective cohort study evaluated baseline demographics, clinical characteristics, and treatment patterns of US patients with asthma who newly initiated single- or multiple-inhaler triple therapy.
This newly-developed prediction model evaluating CAP risk was noted as having demonstrated accuracy, strong discriminatory qualities, and practicability in clinical settings.
Airsupra is the first and only rescue medication approved in the US for as-needed use to reduce risk of asthma exacerbations Approval based on successful Phase III trial programme conducted